33.59
2.41 (7.73%)
| Penutupan Terdahulu | 31.18 |
| Buka | 31.52 |
| Jumlah Dagangan | 1,660,680 |
| Purata Dagangan (3B) | 1,482,626 |
| Modal Pasaran | 3,240,681,472 |
| Harga / Jualan (P/S) | 5.64 |
| Harga / Buku (P/B) | 383.95 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -93.04% |
| Margin Operasi (TTM) | -102.62% |
| EPS Cair (TTM) | -5.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 588.24% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -389.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -172.94 M |
| Pulangan Atas Aset (ROA TTM) | -24.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -377.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ultragenyx Pharmaceutical Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.20% |
| % Dimiliki oleh Institusi | 99.43% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 90.00 (Truist Securities, 167.94%) | Beli |
| Median | 77.50 (130.72%) | |
| Rendah | 50.00 (Barclays, 48.85%) | Beli |
| Purata | 73.75 (119.56%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 32.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 24 Nov 2025 | 50.00 (48.85%) | Beli | 32.78 |
| TD Cowen | 05 Nov 2025 | 75.00 (123.28%) | Beli | 31.87 |
| Truist Securities | 05 Nov 2025 | 90.00 (167.94%) | Beli | 31.87 |
| HC Wainwright & Co. | 09 Sep 2025 | 80.00 (138.17%) | Beli | 31.50 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |